HK Stock Market Move | HIGHTIDE-B(02511) rose by over 6%, and the positive results of the HTD1801 compared head-to-head with Dapagliflozin Phase III clinical trial.

HIGHTIDE-B (02511) surged more than 6%, rising by 6.32% to HK$3.03 at the time of writing, with a trading volume of HK$1,191,900. On the news front, Kin Shing Tai Medicine announced this morning that the clinical Phase III trial (HARMONY) of HTD1801 in patients with type 2 diabetes (T2DM) compared to dapagliflozin achieved positive results, meeting the primary endpoint and showing improvements in multiple key cardiovascular metabolic indicators compared to dapagliflozin. The company stated that following the positive results of the SYMPHONY-1 and SYMPHONY-2 trials, HARMONY is the third Phase III trial of HTD1801 to achieve positive results, further confirming its strong potential as a foundational treatment for cardiovascular metabolic diseases (CKM). Kin Shing Tai Medicine plans to initiate a new drug application (NDA) for the HTD1801 project later this year.